Skip to content

US · KOD · BIOTECHNOLOGY

Kodiak Sciences Inc. (KOD) intrinsic value and stock valuation

$97.17as of 2026-11-21 · Mkt cap 2.73B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kodiak Sciences Inc. DCF and intrinsic value

InvestorsCraft values KOD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KOD’s statements →

Kodiak Sciences Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Palo Alto, CA 94304 kodiak.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$0.00
20162025
Net income
-$-229.97M
20162025
Free cash flow
-$-136.51M
20162025
Total equity
$157.4M-28.8% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-234.39M-$-186.85M-$-277.32M-$-341.38M-$-267.05M
Net income-$-229.97M-$-176.21M-$-260.49M-$-333.82M-$-266.99M
EPSd-$-4.32M-$-3.35M-$-4.97M-$-6.39M-$-5.16M
Operating cash flow-$-136.01M-$-117.32M-$-154.18M-$-206.46M-$-182.27M
Capital expenditure-$-510K-$-400K-$-41.43M-$-47.36M-$-63.3M
Free cash flow-$-136.51M-$-117.72M-$-195.61M-$-253.82M-$-245.57M
Total assets$351.5M$335.6M$479.4M$666.6M$904.2M
Total debt$159.2M$70.3M$181.6M$187.7M$179.9M
Net debt-$-50.68M-$-97.73M-$-103.88M-$-2.7M-$-551.57M
Total equity$157.4M$150.3M$265.8M$436.2M$663.3M
Cash and short-term investments$209.9M$168.1M$285.5M$478.9M$731.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$26.7M$26M$11M$8.71M
Gross profit$0.00-$-26.71M-$-25.95M-$-11M-$-8.71M
Research and development expenses$182.4M$126.1M$206.3M$267.6M$217.3M
Selling, general and administrative expenses$52M$34.1M$71M$62.8M$41M
Other expenses$0.00$0.00-$-25.95M$0.00$0.00
Operating expenses$234.4M$160.1M$251.4M$330.4M$258.3M
Cost and expenses$234.4M$186.9M$277.3M$341.4M$267.1M
Interest income$4.52M$11.2M$16.7M$7.07M$300K
Interest expense$0.00$0.00$10K$20K$20K
Depreciation and amortization$26.3M$26.7M$26M$11M$8.71M
Ebitda-$-203.65M-$-149.5M-$-234.53M-$-322.8M-$-258.26M
Operating income-$-234.39M-$-186.85M-$-277.32M-$-341.38M-$-267.05M
Total other income/expenses, net$4.42M$10.6M$16.8M$7.56M$60K
Income before tax-$-229.97M-$-176.21M-$-260.49M-$-333.82M-$-266.99M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-229.97M-$-176.21M-$-260.49M-$-333.82M-$-266.99M
Weighted average shares outstanding$53.2M$52.6M$52.4M$52.3M$51.8M
Weighted average diluted shares outstanding$53.2M$52.6M$52.4M$52.3M$51.8M
Balance sheet
20252024202320222021
Cash and short-term investments$209.9M$168.1M$285.5M$478.9M$731.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$214.8M$171.9M$289.3M$486M$734.8M
Property, plant and equipment, net$121.9M$148.7M$175M$115.8M$108.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$6.18M$6.18M$6.32M$6.32M$6.32M
Total non-current assets$136.7M$163.6M$190.1M$180.6M$169.4M
Total assets$351.5M$335.6M$479.4M$666.6M$904.2M
Accounts payable$12.9M$3.92M$13.6M$9.13M$12.4M
Short-term debt$12.1M$10.6M$9.77M$9.93M$3.93M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$45.5M$25.6M$41.7M$52.5M$64.7M
Long-term debt$147.1M$59.7M$171.9M$177.8M$176M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$148.6M$159.7M$171.9M$178M$176.2M
Capital lease obligations$47.1M$70.3M$71.9M$77.8M$76.1M
Total liabilities$194.2M$185.3M$213.6M$230.5M$240.9M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.56B-$-1.33B-$-1.15B-$-892.04M-$-558.22M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-1.31M$0.00
Total equity$157.4M$150.3M$265.8M$436.2M$663.3M
Total investments$6.18M$6.18M$6.32M$294.8M$6.32M
Total debt$159.2M$70.3M$181.6M$187.7M$179.9M
Net debt-$-50.68M-$-97.73M-$-103.88M-$-2.7M-$-551.57M
Cash flow statement
20252024202320222021
Net income-$-229.97M-$-176.21M-$-260.49M-$-333.82M-$-266.99M
Depreciation and amortization$18.3M$26.7M$26M$11M$8.71M
Stock-based compensation$58.9M$60.2M$88.6M$106M$61.4M
Change in working capital$6.85M-$-28.39M-$-7.36M$12M$14.4M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$8.07M-$-9.69M$5.6M$1.66M-$-2.09M
Net cash provided by operating activities-$-136.01M-$-117.32M-$-154.18M-$-206.46M-$-182.27M
Investments in property, plant and equipment-$-510K-$-400K-$-41.43M-$-47.36M-$-63.3M
Acquisitions, net$0.00$0.00-$-290K$0.00$0.00
Net cash used for investing activities-$-510K-$-760K$249.2M-$-336.51M-$-38.8M
Common stock issued$178.3M$500K$240K$1.94M$8.23M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$178.3M$500K$30K$1.9M$8.18M
Net change in cash$41.8M-$-117.57M$95.1M-$-541.08M-$-212.89M
Cash at end of period$216.1M$174.3M$285.5M$190.4M$737.8M
Operating cash flow-$-136.01M-$-117.32M-$-154.18M-$-206.46M-$-182.27M
Capital expenditure-$-510K-$-400K-$-41.43M-$-47.36M-$-63.3M
Free cash flow-$-136.51M-$-117.72M-$-195.61M-$-253.82M-$-245.57M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kodiak Sciences Inc.

        Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

        CEO
        Victor Perlroth
        Employees
        124
        Beta
        2.20

        Explore

        Frequently asked questions

        What is the intrinsic value of Kodiak Sciences Inc. (KOD)?

        InvestorsCraft does not currently publish an intrinsic value for KOD. How the IC value is calculated.

        Is KOD undervalued?

        InvestorsCraft does not publish an undervaluation signal for KOD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.